Raymond James & Associates Cassava Sciences Inc Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SAVA
# of Institutions
207Shares Held
14MCall Options Held
2.98MPut Options Held
6.57M-
Black Rock Inc. New York, NY3.22MShares$85.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.52MShares$66.8 Million0.0% of portfolio
-
State Street Corp Boston, MA1.16MShares$30.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$26.7 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO580KShares$15.4 Million7.83% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $1.06B
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...